- Home
- SITE vs INDV Comparison
SITE vs INDV Comparison
Compare SITE & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITE | INDV |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional and commerical equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.4B |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SITE | INDV |
|---|---|---|
| Price | $101.34 | $40.03 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $160.38 | N/A |
| AVG Volume (30 Days) | 629.4K | ★ 1.5M |
| Earning Date | 04-29-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.35 | ★ 8100.00 |
| EPS | N/A | ★ 0.69 |
| Revenue | ★ $4,704,800,000.00 | $1,239,000,000.00 |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $4.08 | N/A |
| P/E Ratio | ★ N/A | $58.73 |
| Revenue Growth | 3.62 | ★ 4.29 |
| 52 Week Low | $98.17 | $16.99 |
| 52 Week High | $168.56 | $42.81 |
Technical Indicators
Market Signals| Indicator | SITE | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 53.44 |
| Support Level | $100.52 | $39.20 |
| Resistance Level | $117.04 | $41.42 |
| Average True Range (ATR) | 3.45 | 1.28 |
| MACD | -0.50 | -0.14 |
| Stochastic Oscillator | 31.48 | 54.81 |
Price Performance
Historical ComparisonAbout SITE SiteOne Landscape Supply Inc.
SiteOne Landscape Supply Inc is a national full product line wholesale distributor of landscape supplies in the United States and has an established presence in Canada. Its customers are mainly residential and commercial landscape professionals who specialized in the design, installation, and maintenance of lawns, gardens, golf courses, and other outdoor spaces.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).